Back to top

crispr: Archive

Zacks Equity Research

Editas (EDIT) Up More Than 70% in Past 3 Months: Here's Why

Editas' (EDIT) lead candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. The company is also developing EDIT-301 for treating hematologic diseases.

BEAMPositive Net Change EDITPositive Net Change NTLAPositive Net Change CRSPPositive Net Change

Sweta Jaiswal, FRM

How Are Genomics ETFs Responding to Q2 Earnings?

Let's take a look at some big genomics earnings releases to see if these will impact ETFs exposed to the space.

BEAMPositive Net Change EDITPositive Net Change PBEPositive Net Change NTLAPositive Net Change CRSPPositive Net Change ARKGPositive Net Change GNOMPositive Net Change IDNAPositive Net Change

Kevin Cook

Bull of the Day: Vertex Pharmaceuticals (VRTX)

Scientific innovation in the treatment of cystic fibrosis bolsters success and pipeline confidence

VRTXNegative Net Change MRNAPositive Net Change CRSPPositive Net Change